close
close

Gottagopestcontrol

Trusted News & Timely Insights

Dallas-based Monarch Waste Technologies opens high-tech pyrolysis plant for medical waste » Dallas Innovates
Alabama

Dallas-based Monarch Waste Technologies opens high-tech pyrolysis plant for medical waste » Dallas Innovates

Dallas-based Monarch Waste Technologies opens high-tech pyrolysis plant for medical waste » Dallas Innovates

According to the Centers for Disease Control and Prevention, the United States generates approximately 3.5 million tons of medical waste each year. Unlike other waste, which is usually sent to a landfill and discarded, medical waste poses three major threats: biological, chemical and safety-related.

These biological hazards can include HIV, tuberculosis, and hepatitis B and C viruses. Chemicals from sprays and splashes can come into contact with the skin or be inhaled. Needle sticks are a major concern, as is the possible presence of toxins and radioactive material, according to the CDC.

That’s why the safe disposal of medical waste is a major national issue – and why finding alternatives to incineration is critical to prevent dangerous emissions from becoming airborne and pumping even more carbon into the atmosphere.

Using Pyrolysis for the disposal of medical waste

This week, Dallas-based Monarch Waste Technologies (MWT) announced “a new benchmark” in medical waste disposal. The company has opened a new facility in Gadsden, Alabama, where a technique called pyrolysis is used to dispose of medical waste.

MWT points out that since 1995, over 99% of medical waste incinerators in the United States have been closed, dramatically increasing the need for new solutions.

Pyrolysis is a process that uses external, indirect heat to decompose medical waste in an oxygen-free environment. At what MWT calls “moderately low temperatures,” the waste slowly “roasts” as it absorbs the heat and decomposes in a sealed, airless chamber. In this “endothermic” process, volatile organic compounds are vaporized in the form of syngas, which is later oxidized at 2,100 degrees Fahrenheit, according to MWT.

The process produces no harmful emissions and produces a “safe, clean, pyrolytic carbon char” that is then disposed of in landfill.

“Almost a decade of teamwork” led to the new facility

MWT’s new Alabama facility utilizes MWT’s third generation PyroMed design, which can process 550 pounds of medical waste per hour.

The company says advances in thermal and material handling components have further optimized the pyrolysis production process, “making this facility reportedly the most technologically advanced pyrolysis system for medical waste destruction ever put into operation. The United States.”

“Our newest plant is the result of nearly a decade of teamwork to take full advantage of the unique environmental benefits of pyrolysis,” said MWT founder and CEO. David Cardenas said in a statement. “Our new Alabama “The plant is the most modern we have ever put into operation and it sets the tone in the industry to drive the development of further plants in the coming years.”

Tommy Kovatch, MWT’s Chief Operating Officer, said, “By leveraging years of reliable operational data, we can ensure that each system we deploy is not only more advanced, but also more economical than the last. This new facility is a testament to our continued commitment to excellence and our goal of being the industry standard for pyrolytic destruction of medical waste.”

“Environmentally conscious” – in a demanding regulatory environment

MWT said the commissioning of the Alabama The plant consolidates its position as a leader in the field of pyrolysis and “as a provider of a proven, sustainable, non-incineration alternative for the environmentally sound destruction of medical waste.”

Bob Bloma compliance expert and facility partner, highlighted the challenges associated with opening a new medical waste facility in today’s regulatory environment.

“From a regulatory perspective, the healthcare waste management industry is extremely challenging, with strict state and federal regulations governing the permitting and operation of a medical waste facility,” Blom said in a statement. “We appreciate the expert and diligent efforts of Alabama state regulators who were able to fully understand the uniqueness of our pyrolysis process and their professionalism in permitting our facility.”

Add yourself to the list.
Dallas innovates every day.

Sign up to stay updated daily on news and events in Dallas-Fort Worth.

CONTINUE READING

  • Rüdiger Nigbur has been promoted to vice president and general manager for Europe, the Middle East and Africa, and Ray Bengermino has been named vice president of U.S. sales. Their leadership positions come at a pivotal time for AnX Robotica, said the company, which holds over 200 patents in the field of advanced medical technology.

  • So how do you start tackling big problems? Tare says it all comes down to the basics: “You start with the basics and think about data collection. What you measure now, you have to measure again in the future to see if there is a trend line.”

  • Industrial process heat is used in the production of everything from the food we eat to the clothes we wear to the steel and paint on our cars. Richardson-based Skyven is working to decarbonize this process with heat recovery systems that reduce carbon emissions—and with public-private funding. The real-world impacts of its California Dairies projects show how Skyven’s model in action reduces emissions and costs.

  • The Advanced Research Projects Agency for Health (ARPA-H) aims to enable 90 percent of all eligible Americans to participate in clinical trials within 30 minutes of their homes. On Thursday, the agency officially opened its new Texas Customer Experience headquarters in Pegasus Park in Dallas, which will serve as the initiative’s home base.

  • UT Southwestern Medical Center and pharmaceutical company Pfizer have partnered to develop new ways to deliver genetic treatments to patients. Together, they hope to accelerate the development of therapies that use RNA biology and artificial delivery methods to address the genetic causes of disease. Pfizer could apply these therapies to its portfolio of research programs.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *